Audio Journal of Cardiovascular Medicine: reporting from American Heart Association Scientific Sessions, Chicago, November 12-15, 2006

Joseph Muhlestein

Sidney Smith

Joost Daemen

Drug Eluting Stents: More Deaths in Real World Use

REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: 2225JOSEPH MUHLESTEIN, University of Utah , Salt Lake CityExtended follow up of 11 000 patients who received drug eluting stents outside the context of clinical trials (in the “real world”) has found an increase in deaths, especially caused by complications in “non-target lesions” – coronary vessels or segments of a vessels which were not the target of the original angioplasty.Joseph Muhlesteintold the AHA meeting this seems to be a real consequence of the drug eluting stents and not just the result of selection.

Drug Eluting Stents; Anti Platelet Therapy: Latest Recommendations

REFERENCE: American Heart Association Scientific Sessions, Chicago, November 12-15, 2006. Abstract: 3236; 2225; 2498SIDNEY SMITH, University of North Carolina, Chapel HillComments on the new findings about drug eluting stents were made during the AHA meeting bySidney Smithwho also gave conference delegates an update on the latest AHA thinking about stent guidelines and also latest recommendations for antiplatelet therapy following angioplasty.

Sirolimus and Paclitaxel Eluting Stents Not Superior to Bare Metal in Patients with Acute Myocardial Infarction After Three Years

American Heart Association Scientific Sessions 2006 November 12-15th Chicago, Illinois. Abstract: 2498JOOST DAEMEN, Erasmus Medical Center, RotterdamDo drug-eluting stents remain superior to bare metal stents after three years follow-up? No, according toJoost Daemenand his group from Rotterdam who told the AHA that both sirolimus and paclitaxel eluting stents don’t bring better long-term outcomes for patients with ST-elevation myocardial infarction. At the AHA conference he discussed his findings with Sarah Maxwell.